Blood Journals Portfolio
Jun 21, 2026, 16:12
Cost Savings and Reduced Factor Consumption With Efanesoctocog Alfa – Blood Journals Portfolio
Blood Journals Portfolio shared a post on X about a recent article by Janice M. Staber et al, adding:
”The high-sustained FVIII therapy efanesoctocog alfa resulted in 3 to 5.5 times lower consumption and may save USD 38 947 to USD 81 000 per surgery.
Read the full study in Blood VTH.”
Title: Cost comparison of efanesoctocog alfa vs conventional factor VIII therapies for major surgeries in patients with severe hemophilia A
Authors: Janice M. Staber, Alix Arnaud, Ion Agirrezabal, Duygu Bozkaya, Lane Anson, Andrew Wilson, Nana Kragh, Doris Quon, Allison P. Wheeler
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 12:43Thomas Dayspring: Reshaping the Biology of Atherosclerotic Plaques with New Therapies
-
Sep 25, 2026, 12:14Garima Sharma: Community Clinical Linkages for Better Postpartum Cardiovascular Care
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis